Linked Life Data

20463365

Source:http://linkedlifedata.com/resource/pubmed/id/20463365

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
31
pubmed:dateCreated
2010-5-13
pubmed:abstractText
Recently, several research groups have described cell surface molecules that are selectively or differentially expressed on leukemia stem cells (LSCs) relative to normal tissue. The identification of these antigens suggests that antibody-based diagnostic or therapeutic opportunities may be forthcoming. Indeed, preclinical studies have suggested the utility of targeting such molecules as a means of enhancing leukemia therapy. Here the current understanding of the LSC phenotype is described, and the potential application of antibody-based treatment regimens is discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1946-6242
pubmed:author
pubmed:issnType
Electronic
pubmed:day
12
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
31ps21
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Targeting myeloid leukemia stem cells.
pubmed:affiliation
Departments of Medicine and Biomedical Genetics and the James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. craig_jordan@urmc.rochester.edu
pubmed:publicationType
Journal Article, Review